Ishita Drugs & Industries Q2 Profit Rises YoY to Rs 0.16 Crore

Revenue from operations reached Rs 3.03 crore during the quarter.
Net profit recorded at Rs 0.16 crore, up from Rs 0.14 crore year-on-year.

Reader Takeaway: YoY profit growth shows stability, but investors should monitor the ongoing facility upgrade execution and rising capex.

What just happened

Ishita Drugs & Industries has released its financial results for the second quarter ending September 30, 2026. The company posted a net profit of Rs 0.16 crore on revenue of Rs 3.03 crore. While quarterly profit saw a marginal sequential dip from Rs 0.23 crore in Q1 FY27, it remains ahead of the Rs 0.14 crore reported in the same quarter last year.

Project Update: Facility Upgradation

A central focus for the management remains the compliance-driven manufacturing facility upgrade, specifically adhering to the Revised Schedule M. The company has invested Rs 4.88 crore to date in structural renovations and new block construction. Operational payments for specialized tasks like HVAC, electrical, and piping work have reached Rs 1.90 crore.

Financing and Debt

The facility upgrade is partially supported by external debt. The company has tapped into its sanctioned term loan from HDFC Bank, with Rs 0.52 crore disbursed so far out of a total facility limit of Rs 9.75 crore. This capital allocation is critical for the long-term operational viability of the company’s manufacturing assets.

What to track next

Shareholders should track the final completion date of the facility upgrades and how efficiently the remaining portion of the HDFC Bank loan is utilized to avoid potential cost overruns. The ability to scale revenue while managing higher overheads from these capital projects will be a key performance indicator for upcoming quarters.